Pacific Biosciences of California Inc. Stock
Heavy losses for Pacific Biosciences of California Inc. today as the stock fell by -€0.099 (-5.520%).
Currently there is a rather positive sentiment for Pacific Biosciences of California Inc. with 10 Buy predictions and 5 Sell predictions.
With a target price of 10 € there is potential for a 478.57% increase which would mean more than doubling the current price of 1.73 € for Pacific Biosciences of California Inc..
Our community identified positive and negative aspects for Pacific Biosciences of California Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pacific Biosciences of California Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Pacific Biosciences of California Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacific Biosciences of California Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pacific Biosciences of California Inc. | -5.520% | -7.404% | 36.481% | -84.443% | -81.544% | -91.851% | -71.740% |
MicroVision Inc | 2.400% | -0.659% | -20.742% | -72.024% | -58.210% | -90.762% | 46.583% |
Fonar Corp. New | 7.580% | -0.699% | -4.698% | -11.801% | -19.774% | -5.960% | -21.849% |
Allscripts Healthcare | - | 0.000% | 4.348% | -34.545% | -22.162% | -47.826% | -17.846% |
Comments
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $7.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat